| Frontiers in Genetics | |
| Gene set variation analysis-based aging and senescence score as a prognostic indicator and therapeutic guide in lung adenocarcinoma | |
| Genetics | |
| Xi He1  Hong Wang2  Tao Lin3  Fangchao Zhao4  Ying Liu5  | |
| [1] Dongguan Marina Bay Central Hospital, Dongguan, China;Tangshan Central Blood Station, Tangshan, China;Tangshan People’s Hospital, Tangshan, China;The Second Hospital of Hebei Medical University, Shijiazhuang, China;Xingtai Third Hospital, Xingtai, China; | |
| 关键词: aging; senescence; lung adenocarcinoma; prognosis; immunotherapy; tumor microenvironment; | |
| DOI : 10.3389/fgene.2023.1176292 | |
| received in 2023-02-28, accepted in 2023-04-12, 发布年份 2023 | |
| 来源: Frontiers | |
PDF
|
|
【 摘 要 】
Accumulating evidence suggests that aging and senescence play crucial roles in tumorigenesis, cancer progression, and treatment. However, the influence of aging and senescence-related genes (ASRGs) on clinical outcomes and treatment options in lung adenocarcinoma (LUAD) patients remains unknown. Here, we developed an aging and senescence-related scoring system, ASRS, by integrating bulk transcriptome data from 22 LUAD datasets. In 3,243 LUAD samples, higher ASRS scores were associated with poor tumor stage and pathological grade, as well as shorter overall survival, disease-free survival, and recurrence-free survival. Additionally, ASRS was associated with different immune patterns in the tumor microenvironment (TME). Importantly, ASRS was found to predict therapeutic efficacy, with patients having a low ASRS benefiting from immunotherapy and those with a high ASRS responding better to chemotherapy. Therefore, ASRS represents a previously overlooked characteristic of LUAD that can influence patient outcomes and treatment success.
【 授权许可】
Unknown
Copyright © 2023 Lin, Wang, Liu, Zhao and He.
【 预 览 】
| Files | Size | Format | View |
|---|---|---|---|
| RO202310102556051ZK.pdf | 6153KB |
PDF